TABLE 6

Incidence of myotoxicity in relationship to dose multiples of the ED50 for plasma TC lowering


Statin

Approximate ED50 (%TC Lowering at Indicated Dose)a

Number of Animals per Treatment Group

Number of Animals with CK >2.5-Fold at 1× ED50

Number of Animals with CK >10-Fold at 1× ED50

Number of Animals with CK >2.5-Fold at 2× ED50

Number of Animals with CK >10-Fold at 2× ED50

Number of Animals with CK >2.5-Fold at 3× ED50

Number of Animals with CK >10-Fold at 3× ED50
Cerivastatinb 1.2 (45.7) 13 6/13 6/13 N.A.c N.A. N.A. N.A.
BMS-423526 0.5 (46.6) 8 0/8 0/8 3/8 0/8 6/8 5/8
Rosuvastatin 50 (49.6) 8 0/8 0/8 1/8 0/8 N.A. N.A.
Pravastatin 200 (24.5)d 5 0/5d 0/5d N.A. N.A. N.A. N.A.
Atorvastatin
50 (48.4)
8
0/8
0/8
0/8
0/8
4/8
0/8
  • a Dose at which plasma TC was lowered by ∼50% relative to vehicle control group. Units for ED50 are milligram/kilogram.

  • b Combined data from Tables 1 and 5 for the 1.2 mg/kg dose of cerivastatin.

  • c N.A., not applicable (statin not dosed at this multiple).

  • d ED50 not reached; 200 mg/kg represents maximal dose tested.